By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

For years, LSN ran an investment banking program for early-stage life science companies. It taught us something important: capital-raising solutions work best when a transaction is imminent. For most early-stage companies, it isn’t. Seed, Series A, and Series B companies are still working through the scientific, clinical, regulatory, commercial, and financing risks that determine whether investors will engage. They pitch technology and market potential. Investors ask what’s been proven, which risks have been retired, and what evidence is still missing. More introductions won’t close that gap. These companies need more than deal preparation. They need a commercialization process that can run for months or years.

The Commercialization Engine
LSN is building one with global partners: universities, research institutes, regional clusters, and innovation programs with technology-rich ecosystems. Our partners advance discoveries, generate evidence, and retire development risks. LSN provides assessment intelligence, investability preparation, and access to the global capital and licensing marketplace. LSN’s agentic AI engines support this process. They help evaluate companies through the eyes of investors and licensing partners, an approach already used with more than 250 clients. They also identify and rank relevant global capital and licensing targets.

Companies enter wherever their readiness puts them. Agentic AI tools are becoming widely available. LSN’s advantage is the global network, relationships, proprietary databases, and market intelligence built through years of direct work with investors, licensing partners, and companies. That depth of intelligence goes well beyond the cursory matches available from web searches.

BD Assist: Where Preparation Becomes Execution
A seasoned CEO may know a few dozen investors and can find a few hundred more. That still isn’t enough. LSN’s Matching Engine generates a Global Target List of 800–1,000 prospective capital and licensing partners. BD Assist puts that intelligence to work through sustained outreach, engagement tracking, and follow-up over the 9–18 months that early-stage campaigns can require. The CEO leads investor relationships, negotiations, and transactions. LSN manages targeting intelligence, sets up the meetings, and provides campaign support. The cost is $5,000 a month, with no success fee. LSN leverages databases that capture current and forward-looking mandates and historical VC and Pharma transactions, then integrates into all of LSN’s RESI events to add face-to-face or virtual meetings with investors and licensing partners worldwide.

Who Is the Perfect Fit for BD Assist?
The ideal client is an experienced life science CEO who knows how to raise capital and has an investable asset and a credible development plan. What they lack is the global reach and campaign infrastructure to pursue hundreds of prospective investors and licensing partners. This CEO doesn’t need someone to explain fundraising or negotiate a term sheet. They need a dedicated team to identify the right global targets, run a disciplined campaign, and keep opportunities moving while they run their company. BD Assist is not for every company that needs money. Companies still working through fundamental scientific or investability issues may first need assessment, de-risking, and preparation.

The CEO knows how to raise the money. LSN provides the global intelligence and reach, including meeting setup and campaign infrastructure, to help them find it.

To see whether BD Assist is the right fit for your company, contact the LSN team. LSN BD will provide a free investability assessment report, show you what your global target list should look like, and offer commentary on your messaging for your target audience.

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

I recently returned from BioJapan, and the one takeaway I want to share with my global network is this: stop viewing Asia Pacific as a single market.

Regulations on both sides of the Pacific have made equity deals between the US and China much harder. But capital hasn’t stopped moving. It has changed form. Where equity deals run into friction, pharma licenses the asset instead. Chinese biotechs out-licensed $60 billion of assets in the first quarter of this year alone, up 73% from the same period a year earlier. That includes AstraZeneca’s deal with CSPC worth up to $18.5 billion. Large pharma faces a steep patent cliff before 2030, so its appetite for clinical-stage assets isn’t going away.

So watch the asset flow, not the equity flow. Here is what actually changed for me in Japan. I went in thinking about APAC as one market with local variations. It isn’t. It is three markets with three completely different jobs, and once you see them separately, the whole region stops looking confusing.

Three Markets, Not One

Each market plays a different role. China produces more assets than its domestic capital can absorb. Australia and Southeast Asia have the clinical infrastructure others can use. Japan and Korea stand out because they have both: a growing supply of academic innovation and deep corporate balance sheets looking for it.

Japan: Where Assets Meet Capital

Universities such as the University of Tokyo, Kyoto University, Keio University, Osaka University, Kobe University, and the University of Tsukuba, with RIKEN anchoring the discovery end, are producing a remarkable range of new assets across drugs, devices, diagnostics, and digital health. What’s new is a coordinated government effort to carry those assets to market:

• AMED runs a 2:1 double match-up program. When a registered VC invests in a Japanese drug discovery startup, AMED can add up to twice that amount in non-dilutive funding, awarded per pipeline rather than per company, so a startup with three approved programs can draw on it three times.
• MEDISO, under the Ministry of Health, Labor and Welfare, pairs ventures and university spinouts with experts in regulatory affairs, international development, and fundraising.
• J-Bridge, run by JETRO, connects international innovators with Japanese corporates.

Three state-backed institutions, answering to different ministries, are working on the same bottleneck, and regional clusters are carrying that work into the field. For global investors and partners, that means Japanese assets now arrive better funded and better prepared, and Japanese corporate capital is easier to reach than it has been in years.

One Japanese advantage almost nobody prices correctly: Japan maintains a conditional, time-limited approval pathway for regenerative medicine products that can grant market access on evidence of probable benefit. No other major market offers that. If you have a cell or gene therapy and have never looked at Japan as a first market rather than a third one, you are leaving an option unexercised.

KBIC, the Kobe Biomedical Innovation Cluster, and LSN are working together to strengthen the commercialization pathway for Japanese life science companies through entrepreneur education, company preparation, capital formation, and international business development. At BioJapan in October, LSN presented joint sessions with KBIC, including one alongside MEDISO, on startup readiness and global fundraising.

RESI Asia: Tokyo and Kobe

That is why RESI is coming to Japan. RESI Asia Japan convenes in Tokyo on April 13, 2027, for global partnering. We expect to announce more events around RESI before and after the 13^th

The Bottom Line

Regulatory boundaries have changed the rules, but pharma’s appetite for licensing shows the underlying science has never been more valuable. Watch the asset flow, not the equity flow. I look forward to seeing many of you in Tokyo next April.

RESI Asia Japan Registration: